SNAP-8

Status

Cosmetic ingredient. No FDA-approved drug labeling exists. Used as a cosmetic ingredient. Cosmetic availability is not FDA approval of a product's claims; disease-treatment or structure/function claims can make a product a drug.

What it is

A topical peptide marketed to soften expression lines.

What published research measured

Acetyl octapeptide-3, a two-residue extension of the acetyl hexapeptide-8 sequence, marketed on the claim that the longer peptide binds the SNARE complex more effectively. The published evidence is thinner than for its shorter relative and is largely supplier-generated rather than independent, with few peer-reviewed controlled studies. The same delivery question applies and applies more forcefully, since an eight-residue hydrophilic peptide crosses intact stratum corneum less readily than a six-residue one. Treat comparative potency claims between these two peptides as marketing rather than as a finding from head-to-head trials, because those trials have not been published.

Source

Not tied to a single designated source; see the published research on this molecule

Sources

No linked primary source is on file for this entry yet.

Educational use only, never medical advice. No doses.